The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice
- Publication date
- 1 December 2011
- Publisher
- 'American Association for Cancer Research (AACR)'